## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : U.S. Appln. No. : Confirmation No. : U.S. Filing Date : Title of Invention : Attny. Docket No. :	To be assigned To be assigned April 19, 2004 Compounds and Methods for	) Art Unit: ) Examiner: Treating Urinar	1626 Fiona T. Powers y Incontinence
Commissioner for F P. O. Box 1450 Alexandria, VA 223			
April 19, 2004			
TRANSMITTA	L LETTER FOR INFORM	ATION DISCL	OSURE STATEMENT
the U.S. Patent and PTO-1449 form and the above-identified	the duty of disclosure under 3' Trademark Office of the docudent which the Examiner may deed application. Copies of the cition No. 09/536,728, filed on 12-2-D1).	ments listed here em relevant to pa tations listed on t	ein and on the attached tentability of the claims of the PTO-1449 form are
§1.53 (d); ii) within 37 C.F.R. §1.491 in on the merits; or iv)	This Statement is being file oplication other than a continuation three (3) months of the date of an international application; is before the mailing of a first Coion under 37 C.F.R. §1.114.	ed prosecution ap of entry of the nat (ii) before the ma	pplication under 33 C.F.R. tional stage as set forth in tiling of a first Office action
notice of allowance	This Statement is being file t before the mailing date of: i) under 37 C.F.R. §1.311, or iii This Statement is being accom	a final action un  an action that of	der 37 C.F.R. §1.113, ii) a
☐ A st	atement as specified in 37 C.F	F.R. §1.97(e) [see	e below]; or
☐ The	fee set forth in 37 C.F.R. §1.1	7(p).	

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski Attorney for Applicant(s)

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4868 Express Mail Label No:. EV403950717US

Date of Deposit: April 19, 2004

I hereby certify that the above papers and fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on April 19, 2004.

Timothy X. Witkowski, Reg. No. 40,232

Please type	a plus	sign (	(+) inside	this t	oox -	<b>→</b>	+
		-					

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	To be assigned	<del></del>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			LOSURE	Filing Date	April 19, 2004		
			PLICANT	First Named Inventor	Esser, F. et al		
				Group Art Unit	1626		
(use as many sheets as necessary)			essary)	Examiner Name	Powers, F.,		
Sheet	1	of	1	Attorney Docket Number	1/1003-4-C3		

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		4,142,051		Rudolf Franzmair	02/27/1979				
		4,226,713		Jack M. Goldberg	10/07/1980				
		4,492,709		Thomas A. Purcell	01/08/1985				
<b> </b>		ļ				n.e.			
┡┈┈┤	-				+				
┞──┤					<del>   </del>				
·					·				
<b> </b>					1				
ļ									
4		I		•	<u> </u>				

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document  Kind Code <sup>5</sup> Office <sup>3</sup> Number <sup>4</sup> (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6		
		WO	88/07995	A2	Laboratoires Alcon S.A.	10/20/1988				
		EP	0 030 616	B1	C.H.Boehringer Sohn	06/24/1981				
		EP	0 073 394	A1	Bayer AG	09/03/1983				
		wo	95/19968	A1	Allergan, Inc.	07/27/1995				
		GB	1,216,945		B.I. GmbH	12/23/1970				
		GB	1,450,250		Chemie Linz Aktienges	09/22/1976				
		EΡ	00/81923		Alcon Laboratories	06/22/1983		<del> </del>		
						<del> </del>		+		

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.